Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Blautix in Adults with IBS-C and IBS-D
2018-001203-36Phase 2Completed
- Sponsor
- 4D Pharma plc
- Start
- Apr 2018
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in irritable bowel syndrome (IBS) and Diarrhea-predominant irritable bowel syndrome (IBS-D) comparing Blautix BID with Placebo BID (2 arms). Primary endpoint: Overall responder status. Started Apr 2018; status: completed.
02
Drugs
blautix
03
Conditions
irritable bowel syndrome (IBS)Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on 2018-001203-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001203-36.